4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-037740
President & Immunovant CEO sold 665,159 shares at an average $16.21 ($10,781,813)
- President & Immunovant CEO acquired 665,159 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2025-10-06 | Option exercise 10b5-1 | +127,355 | $15.85 | $2,018,577 | 1,632,314 | D |
| Venker Eric President & Immunovant CEO | 2025-10-06 | Option exercise 10b5-1 | +24,900 | $7.45 | $185,505 | 1,657,214 | D |
| Venker Eric President & Immunovant CEO | 2025-10-06 | Option exercise 10b5-1 | +19,141 | $3.85 | $73,693 | 1,676,355 | D |
| Venker Eric President & Immunovant CEO | 2025-10-06 | Sale 10b5-1 | −171,396 | $16.34 | $2,800,611 | 1,504,959 | D |
| Venker Eric President & Immunovant CEO | 2025-10-07 | Option exercise 10b5-1 | +67,171 | $15.85 | $1,064,660 | 1,572,130 | D |
| Venker Eric President & Immunovant CEO | 2025-10-07 | Option exercise 10b5-1 | +107,131 | $7.45 | $798,126 | 1,679,261 | D |
| Venker Eric President & Immunovant CEO | 2025-10-07 | Option exercise 10b5-1 | +180,859 | $3.85 | $696,307 | 1,860,120 | D |
| Venker Eric President & Immunovant CEO | 2025-10-07 | Sale 10b5-1 | −355,161 | $16.15 | $5,735,850 | 1,504,959 | D |
| Venker Eric President & Immunovant CEO | 2025-10-08 | Option exercise 10b5-1 | +10,307 | $15.85 | $163,366 | 1,515,266 | D |
| Venker Eric President & Immunovant CEO | 2025-10-08 | Option exercise 10b5-1 | +128,295 | $7.45 | $955,798 | 1,643,561 | D |
| Venker Eric President & Immunovant CEO | 2025-10-08 | Sale 10b5-1 | −138,602 | $16.20 | $2,245,352 | 1,504,959 | D |
| Derivatives | |||||||
| Venker Eric President & Immunovant CEO | 2025-10-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −127,355 | 1,054,528 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −24,900 | 235,426 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,141 | 6,457,382 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −67,171 | 987,357 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −107,131 | 128,295 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −180,859 | 6,276,523 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-08 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,307 | 977,050 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-08 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −128,295 | 0 | D | ||
| Open-market sales · 665,159 sh · avg $16.21 · $10,781,813 | |||||||
Loading xslF345X05/form4.xml…